Back
Pacira BioSciences Quote, Financials, Valuation and Earnings
Sponsored
PCRX
Sponsored
Unlock the Secret to Earning Monthly Income!
Limited spots act swiftly
Sell
48
PCRX
Pacira BioSciences
Last Price:
27.00
Seasonality Move:
2.24%
7 Day Trial
ALL ACCESS PASS
$
7
My #1 Coin is...
All the details are on the next page.Pacira BioSciences Price Quote
$27.00
-0.21 (-0.77%)
(Updated: May 6, 2024 at 11:55 AM ET)
Pacira BioSciences Key Stats
Sell
48
Pacira BioSciences (PCRX)
is a Sell
Day range:
$27.05 - $27.77
52-week range:
$25.33 - $43.81
Dividend yield:
0%
P/E ratio:
30.57
P/S ratio:
2.21
P/B ratio:
1.45%
Volume:
247.3K
Avg. volume:
432.8K
1-year change:
-36.9%
Market cap:
$1.3B
Revenue:
$675M
EPS:
$0.83
How Much Does Pacira BioSciences Make?
-
How Much Are Pacira BioSciences's Sales Annually?
PCRX Revenues are $675M -
How Much Profit Does Pacira BioSciences's Make A Year?
PCRX net income is $42M
Is Pacira BioSciences Growing As A Company?
-
What Is Pacira BioSciences's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.05% -
What Is Pacira BioSciences's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Pacira BioSciences Stock Price Performance
-
Did Pacira BioSciences Stock Go Up Last Month?
Pacira BioSciences share price went down by -6.2% last month -
Did PCRX's Share Price Rise Over The Last Year?
PCRX share price fell by -36.9% over the past 1 year
What Is Pacira BioSciences 52-Week High & Low?
-
What Is Pacira BioSciences’s 52-Week High Share Price?
Pacira BioSciences has traded as high as $43.81 over the past 52 weeks -
What Is Pacira BioSciences’s 52-Week Low Share Price?
Pacira BioSciences has traded as low as $25.33 over the past 52 weeks
Pacira BioSciences Price To Free Cash Flow
-
Is Pacira BioSciences Stock Overvalued?
Pacira BioSciences is trading at a price to free cash flow ratio of 10.68 -
Is Pacira BioSciences Stock Undervalued?
Pacira BioSciences EV to Free Cash Flow ratio is 10.82 -
What Is Pacira BioSciences’s Price Earnings Growth Ratio?
PCRX PEG ratio is 0.20 -
Is Pacira BioSciences Trading At A Premium To Earnings?
Pacira BioSciences EV to EBIT ratio is 19.10
Is It Risky To Buy Pacira BioSciences?
-
How Much Debt Does Pacira BioSciences Have?
Total long term debt quarterly is $522.4M -
How Much Cash Does Pacira BioSciences Have?
Cash and short term investments quarterly total is $278.6M -
What Is Pacira BioSciences’s Book Value Per Share?
Book value per share is 18.72
Is Pacira BioSciences Cash Flow Positive?
-
What Is PCRX Cash Flow From Operations?
Cash flow from operations (TTM) is $154.6M -
What Is Pacira BioSciences’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$183M -
What Is Pacira BioSciences’s Cash Flow From Investing?
Cash flow from investing (TTM) is $77.5M
Pacira BioSciences Return On Invested Capital
-
Is Management Doing A Good Job?
PCRX return on invested capital is 3.04% -
What Is Pacira BioSciences Return On Assets?
ROA measures how assets are converting to revenues and is 2.67% -
What Is PCRX Return On Equity?
ROE is a measure of profitability and is 5.18%
Pacira BioSciences Earnings Date & Stock Price
-
What Is Pacira BioSciences's Stock Price Today?
A single share of PCRX can be purchased today for 27.21 -
What Is Pacira BioSciences’s Stock Symbol?
Pacira BioSciences trades on the nasdaq under the ticker symbol: PCRX -
When Is Pacira BioSciences’s Next Earnings Date?
The next quarterly earnings date for Pacira BioSciences is scheduled on May 7, 2024 -
When Is PCRX's next ex-dividend date?
Pacira BioSciences's next ex-dividend date is May 6, 2024 -
How To Buy Pacira BioSciences Stock?
You can buy Pacira BioSciences shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Pacira BioSciences Competitors
-
Who Are Pacira BioSciences's Competitors?
Below is a list of companies who compete with Pacira BioSciences or are related in some way:
Pacira BioSciences Dividend Yield
Data Unavailable
Pacira BioSciences Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 4.6% |
Revenue: | 5.4% | 0.21% |
Analyst Recommendations
Buy Recommendations: | 4 |
---|---|
Hold Recommendations: | 0 |
Sell Recommendations: | 0 |
Price Target: | 45.73 |
Upside from Last Price: | 68.05% |